A Randomized Double Blind Study of Cabozantinib in Combinaiton with Nivolumab and Ipilimumab vs Nivolumab and Ipilimumab in Patients with Previously Untreated Advanced or Metastatic Renal Cell Cancer of Intermediate or Poor Risk (XL184-313)
A Randomized Double Blind Study of Cabozantinib in Combinaiton with Nivolumab and Ipilimumab vs Nivolumab and Ipilimumab in Patients with Previously Untreated Advanced or Metastatic Renal Cell Cancer of Intermediate or Poor Risk (XL184-313)
Trial Category:
Genitourinary
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
